Clinical Trial Update: The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and effects of gefitinib in patients with EGFR-positive triple-negative metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Iressa (Gefitinib) (Gefitinib)

Snippet

Sponsor: Jiangmen Central Hospital | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN